{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T02:57:41Z","timestamp":1768273061144,"version":"3.49.0"},"reference-count":19,"publisher":"BMJ","issue":"5","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Arch Dis Child Fetal Neonatal Ed"],"accepted":{"date-parts":[[2016,12,20]]},"published-print":{"date-parts":[[2017,9]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To evaluate the role of prophylactic propranolol in the prevention of retinopathy of prematurity (ROP) in infants \u226432\u2005weeks of gestational age and their visual outcome at 1\u2005year of corrected gestational age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>Randomised double blind placebo controlled trial, parallel group nrolment with allocation ratio of 1:1.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Settings<\/jats:title>\n                  <jats:p>Two level III neonatal intensive care units.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>109 preterm neonates of \u226432\u2005weeks of gestation with postnatal age \u22648\u2005days old.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>\n                     <jats:italic>Study group:<\/jats:italic> Infants with gestational age between 26 and 32\u2005weeks were started on propranolol prophylaxis (0.5\u2005mg\/kg\/dose every 12 hours) on seventh completed day of life, till a corrected gestational age of 37\u2005weeks or complete vascularisation of retina whichever was later. <jats:italic>Control group<\/jats:italic> infants received a placebo.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcome measures<\/jats:title>\n                  <jats:p>\n                     <jats:italic>Primary<\/jats:italic>: ROP of all grades; <jats:italic>Secondary<\/jats:italic>: evaluation of complications due to propranolol, ROP needing treatment with laser and\/or antivascular endothelial growth factor (anti-VEGF) and visual outcome at 12\u2005months corrected age.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Prophylactic propranolol in the prescribed dose of 1\u2005mg\/kg\/day showed a decreasing trend in the incidence of ROP (56.8% vs 68.6%; p=0.39), need for laser therapy (21.56% vs 31.37%; p=0.37), treatment with anti-VEGF (3.92% vs 15.68%; p=0.09) or visual outcomes at 1\u2005year in the study and control groups, respectively, though these reductions were not statistically significant. Decreasing trends favouring propranolol in all other ROP-related outcomes were also noted in the study group.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Prophylactic propranolol in the prescribed dose of 1\u2005mg\/kg\/day showed a decreasing trend in all outcomes of ROP though statistically not significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>CTRI\/2013\/11\/004131.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/archdischild-2016-311548","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T21:50:43Z","timestamp":1484344243000},"page":"F389-F394","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":24,"title":["Prophylactic propranolol for prevention of ROP and visual outcome at 1\u2005year (PreROP trial)"],"prefix":"10.1136","volume":"102","author":[{"given":"Kishore Pratap","family":"Sanghvi","sequence":"first","affiliation":[{"name":"Department of Pediatrics and Neonatology, Jaslok Hospital and Research Centre, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nandkishor S","family":"Kabra","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Surya Children's Hospital, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phalguni","family":"Padhi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Surya Children's Hospital, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umesh","family":"Singh","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Jaslok Hospital and Research Centre, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Swarup Kumar","family":"Dash","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Surya Children's Hospital, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhupendra S","family":"Avasthi","sequence":"additional","affiliation":[{"name":"Department of Pediatrics and Neonatology, Surya Children's Hospital, Mumbai, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"key":"2025090503445163000_102.5.F389.1","doi-asserted-by":"publisher","DOI":"10.2741\/1056"},{"key":"2025090503445163000_102.5.F389.2","doi-asserted-by":"publisher","DOI":"10.1242\/dev.01732"},{"key":"2025090503445163000_102.5.F389.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc0708819"},{"key":"2025090503445163000_102.5.F389.4","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2008-3458"},{"key":"2025090503445163000_102.5.F389.5","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-0803"},{"key":"2025090503445163000_102.5.F389.6","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-5536"},{"key":"2025090503445163000_102.5.F389.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2013.07.049"},{"key":"2025090503445163000_102.5.F389.8","first-page":"285c","article-title":"Hypotension in preterm infants","volume":"45","author":"Hafis Ibrahim","year":"2008","journal-title":"Indian Pediatr"},{"key":"2025090503445163000_102.5.F389.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-3782(99)00038-9"},{"key":"2025090503445163000_102.5.F389.10","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.123.7.991"},{"key":"2025090503445163000_102.5.F389.11","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2005-2749"},{"key":"2025090503445163000_102.5.F389.12","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.098582"},{"key":"2025090503445163000_102.5.F389.13","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318177f934"},{"key":"2025090503445163000_102.5.F389.14","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318159ec6b"},{"key":"2025090503445163000_102.5.F389.15","doi-asserted-by":"publisher","DOI":"10.1136\/archdischild-2013-303951"},{"key":"2025090503445163000_102.5.F389.16","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1515\/jpm-2015-0357","article-title":"Oral Propranolol in early stages of retinopathy of prematurity","volume":"44","author":"Bancalari","year":"2016","journal-title":"J Perinat Med"},{"key":"2025090503445163000_102.5.F389.17","doi-asserted-by":"crossref","unstructured":"Korkmaz L , Ba\u015ftu\u011f O , Ozdemir A , et al . The efficacy of propranolol in retinopathy of prematurity and its correlation with the platelet mass index. Curr Eye Res 2016:1\u201310. DOI: 10.3109\/02713683.2016.1158272 doi:10.3109\/02713683.2016.1158272","DOI":"10.3109\/02713683.2016.1158272"},{"key":"2025090503445163000_102.5.F389.18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000381659","article-title":"Oral propranolol: a new treatment for infants with retinopathy of prematurity?","volume":"108","author":"B\u00fchrer","year":"2015","journal-title":"Neonatology"},{"key":"2025090503445163000_102.5.F389.19","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1651-2227.2011.02330.x","article-title":"On the use of antiangiogenetic medications for retinopathy of prematurity","volume":"100","author":"H\u00e5rd","year":"2011","journal-title":"Acta P\u00e6diatrica"}],"container-title":["Archives of Disease in Childhood - Fetal and Neonatal Edition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/archdischild-2016-311548","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T10:45:00Z","timestamp":1757069100000},"score":1,"resource":{"primary":{"URL":"https:\/\/fn.bmj.com\/lookup\/doi\/10.1136\/archdischild-2016-311548"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":19,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,8,18]]},"published-print":{"date-parts":[[2017,9]]}},"alternative-id":["10.1136\/archdischild-2016-311548"],"URL":"https:\/\/doi.org\/10.1136\/archdischild-2016-311548","relation":{},"ISSN":["1359-2998","1468-2052"],"issn-type":[{"value":"1359-2998","type":"print"},{"value":"1468-2052","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}